The company announces that it has started selling CERAMENT BVF direct via its own US distributor network.
“The launch of our own US distribution network is a key strategic milestone as we work towards our goal of becoming a global orthobiologics leader focused on the treatment of bone voids. Gaining control of our destiny in the US delivers multiple significant benefits that we are confident will allow us to build a much stronger BONESUPPORT business and deliver significant value to all of our stakeholders,” said Emil Billbäck, BONESUPPORT’s CEO.
The company created its own network of distributors and expanded its US commercial organization to access a much larger market opportunity for CERAMENT BVF, increase its ability to drive end-user sales, deliver higher net margins, expand its US product offering and raise brand awareness ahead of the CERAMENT G launch, it states.
Strengthen US commercial platform
BONESUPPORT ‘s US network currently consists of 25 distributors, that cover all key areas of the US bone void filler market that the company is targeting. Together these distributors employ a total of 512 sales reps. This strengthened US commercial platform will launch new products from its recent agreements with Collagen Matrix Inc. and MTF Biologics, which are complementary to CERAMENT BVF, in the first half of 2019.
BONESUPPORT terminated its exclusive distribution agreement for CERAMENT BVF with Zimmer Biomet (ZB) for the US market in May 2018. Under the terms of this agreement, ZB’s exclusivity expired on 20 October 2018. ZB will continue to be a non-exclusive distributor of CERAMENT BVF until 21 April 2019.